Non-Hodgkin Lymphoma Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Non-Hodgkin Lymphoma Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

“DelveInsight Business Research LLP”
DelveInsight’s “Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

NHL is a type of blood cancer that initially started in the white blood cells (WBCs) called lymphocytes, it is also known as non-Hodgkin’s disease. Commonly the NHL occurs from lymph nodes at one or more places in the body, which can progress through the lymphatic system from one group of lymph nodes to another. It can occur at any age and are often marked by enlarged lymph nodes, fever, night sweats, and weight loss. There are different types of, and these are divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can and can develop from either B-cells or T-cells or Natural killer (NK) cells. Most of the cases of NHL are B-cell NHL (nearly 85%). T-cell lymphomas make up less than 15% of NHL.  

Get FREE sample copy at:



The Non-Hodgkin Lymphoma market report also covers emerging drugs, current treatment practices, Non-Hodgkin Lymphoma market share of the individual therapies, current and forecasted Non-Hodgkin Lymphoma Market Size from 2017 to 2030 segmented by seven major markets.

The report provides a detailed current Non-Hodgkin Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 


Non-Hodgkin Lymphoma Market Key Facts

The total incident cases of NHL in the 7MM was 166,909 in 2017, and are expected to increase during the study period during the study period [2017–2030].

Among the 7MM, as per the estimates, the highest Incident population of NHL was in the United States, i.e., 61,080 B-cell NHL (in 2017). B-cell lymphomas make up most (about 85%) of the NHL cases.

Among the European-5 countries, Germany had the highest incident population of NHL, followed by the United Kingdom and France. On the other hand, Spain had the lowest incident cases of NHL in 2017.

NHL cases are most common in middle-aged and older adults. In comparison, they are relatively less common in children and young adults. It is estimated that the most incident age-group for NHL among the 7MM was 65–74 years in 2017. Patients of age groups 55–64 years were observed to be the second-highest in 2017.


Key Benefits of Non-Hodgkin Lymphoma Market Report

  • Non-Hodgkin Lymphoma market report provides an in-depth analysis of Non-Hodgkin Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Non-Hodgkin Lymphoma market report will help in developing business strategies by understanding the Non-Hodgkin Lymphoma Market trends & developments, key players and future market competition that will shape and drive the Non-Hodgkin Lymphoma market in the upcoming years.

  • The Non-Hodgkin Lymphoma market report covers Non-Hodgkin Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Non-Hodgkin Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Non-Hodgkin Lymphoma Market

There are several treatment options for NHL, which include chemotherapy, radiation, and immunotherapy. The choice of treatment option is dependent on the type of B-cell Lymphoma, symptoms, age, and how fast it is growing and whether patients may suffer various patterns of recurrence requiring subsequent lines of rescue therapies. Chemotherapy is a widely used treatment for NHL. It may be used on its own, combined with biological therapy, or combined with radiotherapy. The medication can be given in a number of different ways, depending on the Stage of the cancer.

Owing to the launch of upcoming therapies, the market size of Non-Hodgkin Lymphoma is expected to increase significantly during the forecast period (2020–2030).

The Non-Hodgkin Lymphoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Non-Hodgkin Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Non-Hodgkin Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 


Non-Hodgkin Lymphoma Epidemiology

The Non-Hodgkin Lymphoma epidemiology section covers insights about historical and current Non-Hodgkin Lymphoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Non-Hodgkin Lymphoma Drugs Uptake and Key Market Players

The Non-Hodgkin Lymphoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Hodgkin Lymphoma market or expected to get launched in the market during the study period. The analysis covers Non-Hodgkin Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the NHL market is anticipated to change in the coming years owing to the launch of emerging therapies during the forecast period of 2020–2030. Major Pharma giants are thoroughly working toward the development of new treatment therapies, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with NHL. Some of the Key players involved in developing therapies for NHL includes:
Bristol-Myers Squibb
Gilead Sciences
MorphoSys AG
TG Therapeutics
Xynomic Pharmaceuticals
Hoffmann-La Roche
Merck Sharp & Dohme
Gilead Sciences
And several others


Drugs Covered
Tafasitamab (MOR208; formerly XmAb 5574)
Lisocabtagene maraleucel (JCAR017)
Enzastaurin Hydrochloride (DB102)
Avelumab (Bavencio)
Umbralisib (TG-1202)
And many others.


Table of Content

1. Key Insights

2. Executive Summary 

3. Non-Hodgkin Lymphoma Competitive Intelligence Analysis

4. Non-Hodgkin Lymphoma Market Overview at a Glance

5. Non-Hodgkin Lymphoma Disease Background and Overview

6. Non-Hodgkin Lymphoma Patient Journey

7. Non-Hodgkin Lymphoma Epidemiology and Patient Population

8. Non-Hodgkin Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Hodgkin Lymphoma Unmet Needs

10. Key Endpoints of Non-Hodgkin Lymphoma Treatment

11. Non-Hodgkin Lymphoma Marketed Products

12. Non-Hodgkin Lymphoma Emerging Therapies

13. Non-Hodgkin Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Non-Hodgkin Lymphoma Market Outlook (7 major markets)

16. Non-Hodgkin Lymphoma Access and Reimbursement Overview

17. KOL Views on the Non-Hodgkin Lymphoma Market.

18. Non-Hodgkin Lymphoma Market Drivers

19. Non-Hodgkin Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


Related Reports

Non-Hodgkin’s Lymphoma (NHL) Epidemiology Forecast to 2030

DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Non-Hodgkin’s Lymphoma (NHL) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


Non-Hodgkin’s Lymphoma (NHL) Pipeline Insights, 2020

Non-Hodgkin’s Lymphoma (NHL) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non-Hodgkin’s Lymphoma (NHL) market.


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States